The cost–effectiveness of PCV use depends on many factors, including the burden of disease, vaccine effectiveness, indirect effects, vaccination coverage, vaccine price, delivery costs and schedule. Go to footnote 1, Go to footnote 2 An analysis of data from 22 studies in low- and middle-income countries showed that vaccination with PCV10-GSK and PCV13-PFZ using a 3p+0 or 2p+1 schedule is cost-effective from the perspectives of both the healthcare system and society. Go to footnote 2 The cost-effectiveness according to product choice will depend on country characteristics, including local serotype distribution and coverage rates achieved with different schedules. Go to footnote 1, Go to footnote 2, Go to footnote 3, Go to footnote 4
- Go back to footnote reference 1aGo back to footnote reference 1b
Chaiyakunapruk N, Somkrua R, Hutubessy R, Henao AM, Hombach J, Melegaro A et al. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. BMC Med. 2011;9:53. doi: 10.1186/1741-7015-9-53.
- Go back to footnote reference 2aGo back to footnote reference 2bGo back to footnote reference 2c
Saokaew S, Rayanakorn A, Wu DB, Chaiyakunapruk N. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. Pharmacoeconomics. 2016;34:1211-25. doi: 10.1007/s40273-016-0439-3.
- Go back to footnote reference 3
Krishnamoorthy Y, Eliyas SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. Vaccine. 2019;37:623-30. doi: 10.1016/j.vaccine.2018.12.004.
- Go back to footnote reference 4
Dilokthornsakul P, Kengkla K, Saokaew S, Permsuwan U, Techasaensiri C, Chotpitayasunondh T et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 2019;37:4551-60. doi: 10.1016/j.vaccine.2019.06.015.
